soul trial oral semaglutide cardiovascular outcomes nejm 2025 results

soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Abstract 4351008: Comparing in New Users of Versus Other Noninsulin Glucose-Lowering Therapies Targeting the weight within: obesity – Oral Semaglutide Reduces Cardiovascular Events

Name: soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Abstract 4351008: Comparing in New Users of Versus Other Noninsulin Glucose-Lowering Therapies Targeting the weight within: obesity – Oral Semaglutide Reduces Cardiovascular Events
Brand: kongresftb.pl
SKU: 39371155578
Price: 24.96 USD
Availability: InStock
Rating: 4.4635 (30 reviews)

SKU: 39371155578

4.5

USD24.96 USD47.96

Pay in 4 interest-free payments of $6.24 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 28 - Sep 2

Description

Asia-Pacific (including Japan) - Strongest growth region supported by rising diabetic population, expanding healthcare access, increasing awareness, and large-scale pharmaceutical manufacturing in China, India, and Southeast Asia, along with Japan's advanced diabetes care ecosystem